Selumetinib granule formulation

Phase 2

ASTRAZENECA PLC (AZNCF)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Neurofibromatosis Type 1

View Full Landscape

Drug Information

Target Indication

Neurofibromatosis Type 1

Clinical Trial

NCT05309668

Last updated: 4/10/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA6/17/2021

Koselugo

Koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adult and paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and older. Koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in patients with neurofibromatosis type 1 (NF1) aged 1 year to less than 7 years and for older patients with swallowing difficulties.

OrphanConditional

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

AZNCF

ASTRAZENECA PLC

Biotechnology•North America•NASDAQ

Related Pipeline

Quetiapine SRPhase 3

Anxiety Disorders

MEDI3250Phase 3